Compare Strategy Inc. (MSTR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs TransMedics Group Inc — how do they compare? Strategy Inc. trades at $132.14 (market cap $54.24B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Strategy Inc. is far larger — about 17.7× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| MSTR | TMDX | |
|---|---|---|
Market Cap | $54.24B | $3.06B |
Sector | Technology | Technology |
52-Week High | $359.69 | $150.42 |
52-Week Low | $82.31 | $61.99 |
Enterprise Value | $73.00B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $136.52, down 4.4% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of -$24.45, missing estimates, and has a negative net income margin of -6,102.96%. Recent news highlights a $176.3 million preferred stock buyback instead of Bitcoin purchases, and a partnership with Google Cloud for an AI forum series.
The outlook is mixed: analyst consensus is bullish with a $229.64 price target, but significant risks include persistent earnings misses, high debt, and negative profitability. The stock's performance is heavily tied to Bitcoin market sentiment, posing volatility risks despite institutional interest.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
